New inhaler propellant tested in mild asthma study

NCT ID NCT06433921

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new propellant (HFA-152a) in salbutamol inhalers works as well as the current one (HFA-134a) for people with mild asthma. 84 adults aged 18-65 will receive single doses of the inhaler or a placebo. The main goal is to measure how well the inhaler protects against airway narrowing triggered by a substance called methacholine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: salbutamol (albuterol) inhaler with a new propellant (HFA-152a)
What this could lead to: If successful, this could show that the new propellant works just as well as the current one, potentially leading to a more environmentally friendly inhaler option.
What could go wrong: This is an early phase 1 study with only 84 people, so results may not apply to everyone. The new propellant might not work as well or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA MILD ASTHMA

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Manchester, M23 9QZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.